{
  "id": 764128,
  "title": "Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest",
  "url": "https://urgent.news/2026/08/13/taiho-cullinans-lung-cancer-drug-passes-phase-3-test-lining-up",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-13T11:11:47.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/taiho-cullinans-lung-cancer-drug-passes-phase-3-test-lining-up-rybrevant-contest/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Taiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer. The companies’ oral drug, called zipalertinib, plus ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "BioPharma Dive",
        "title": "New Taiho, Cullian data heats up lung cancer drug battle",
        "url": "https://urgent.news/2026/08/13/new-taiho-cullian-data-heats-up-lung-cancer-drug-battle",
        "published": "2026-08-13T16:05:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}